Pharma Pulse: AI’s $120M Cardiometabolic Play

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, the American Academy of Pediatrics has released their own 2026 vaccine schedule in direct response to the recent HHS overhaul. While federal guidelines moved six routine vaccines to shared decision-making, the AAP is re-endorsing all 18 immunizations for US children.
• In supply chain news, Morris & Dickson has officially acquired Prodigy Health. This significantly boosts the distributor’s reach into high-cost plasma-derived therapies and specialty care settings.
• Lastly, Insilico Medicine has inked a $120 million deal with Qilu Pharmaceuticals. The company will be using Insilico’s Pharma.AI platform to design novel small molecules, aiming to slash discovery timelines for cardiometabolic diseases.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.